Kinedak

Kinedak is an early-stage biotechnology company dedicated to pioneering new approaches in kinase-targeted therapies. Founded by a team of distinguished chemical biologists including Kevan Shokat, Nathanael Gray, and Eric Fischer, the company focuses on addressing the limitations of traditional kinase inhibitors. By utilizing advanced chemical biology and targeted protein degradation techniques, Kinedak aims to develop potent and selective small molecules for previously "undruggable" kinases. The company's platform integrates chemical proteomics and structural biology to identify novel binding sites and mechanisms of action. Kinedak's mission is to provide transformative treatments for patients with cancer and other diseases driven by kinase dysregulation.